EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mechanistic insights into dual-active liver and blood-stage antiplasmodials

Mukul Rawat iD, Nonlawat Boonyalai, Cindy Smidt, Madeline R Luth, Daisy Chen, Andrew Plater, John Post, De Lin, Joel McMillan, Thomas Eadsforth, Sonia Moliner-Cubel, Oliver Billker und 5 weitere

mBio · 14.01.2026 · 17 (1)

DOI: 10.1128/mbio.02423-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, erschienen am 14.01.2026. Verfasst von Mukul Rawat und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Biological Chemistry and Drug Discovery, Wellcome Centre for Anti-Infectives Research, University of Dundee, Dundee, United Kingdom. Hauptthemen laut MEDLINE: Antimalarials, Plasmodium falciparum, Liver. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bill and Melinda Gates Foundation, NIGMS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The identification of novel antimalarials with activity against both the liver and blood stages of the parasite lifecycle would have the dual benefit of prophylactic and curative potential. However, one challenge of leveraging chemical hits from phenotypic screens is subsequent target identification. Here, we use in vitro evolution of resistance to investigate nine compounds from the Tres Cantos Antimalarial Set (TCAMS) with dual liver and asexual blood stage activity. We succeeded in eliciting resistance to four compounds, yielding mutations in acetyl CoA synthetase (AcAS), cytoplasmic isoleucine tRNA synthetase (cIRS), and protein kinase G (PKG), respectively. Using a combination of CRISPR editing and in vitro activity assays with recombinant proteins, we validate these as targets for TCMDC-125075 (AcAS), TCMDC-124602 (cIRS), TCMDC-141334, and TCDMC-140674 (PKG). Notably, for the latter two compounds, we obtained a T618I mutation in the gatekeeper residue of PKG, consistent with direct interaction with the active site, which we modeled with molecular docking. Finally, we performed cross-resistance evaluation of the remaining five resistance-refractory compounds using the Antimalarial Resistome Barcode sequencing assay (AReBar), which examined a pool of 52 barcoded lines with mutations covering >30 common modes of action. None of the five compounds where in vitro evolution of resistance was not successful yielded validated hits using AReBar, indicating they likely act via novel mechanisms and may be candidates for further exploration. IMPORTANCE Despite recent progress in the development of the next generation of antimalarial drug candidates, the risk of resistance remains. Thus, the identification of new targets that are essential at multiple stages of the malaria parasite lifecycle is an important priority. Validation of targets essential for the liver-stage not only would be relevant for prophylaxis but may also limit the potential generation of resistance due to the lower parasite numbers encountered at this stage. Here, we have leveraged compounds with dual liver- and blood-stage activity, combined with evolution of resistance, to chemically validate targets with multi-stage essentiality. We successfully evolved resistance to four, which we further characterize by genome sequencing, CRISPR editing and biochemical assays. The remaining five resistance-refractory compounds showed no interactions when profiled against a barcoded parasite library representing >30 known modes of action, suggesting these may have novel targets and represent interesting starting points for further exploration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntimalarialsPlasmodium falciparumLiverDrug ResistanceHumansMutationProtozoan Proteins

Stichwörter der Autor:innen

antimalarial agentsdrug resistance mechanismsmalaria

Substanzen

AntimalarialsProtozoan Proteins

Autor:innen und Institutionen

  • Division of Biological Chemistry and Drug Discovery, Wellcome Centre for Anti-Infectives Research, University of Dundee, Dundee, United Kingdom.
  • Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.
  • Department of Pediatrics, University of California San Diego, La Jolla, California, USA.
  • Bioinformatics and Systems Biology Graduate Program, University of California San Diego, La Jolla, California, USA.
  • Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Science, University of Dundee, Dundee, United Kingdom.
  • Global Health Medicines R&D, GSK, Severo Ochoa, Tres Cantos, Spain.

ORCID-Profile: Mukul Rawat, Julian C Rayner, Marcus C S Lee

Förderung

  • Bill and Melinda Gates Foundation
  • NIGMS NIH HHS
  • NIH HHS
  • Wellcome Trust
  • Tres Cantos Open Lab Foundation
  • National Institute of General Medical Sciences

Zitieren

APA

Rawat, M., Boonyalai, N., Smidt, C., Luth, M. R., Chen, D., Plater, A., Post, J., Lin, D., McMillan, J., Eadsforth, T., Moliner-Cubel, S., Billker, O., Rayner, J. C., Gamo, F. J., Baragaña, B., Winzeler, E. A., & Lee, M. C. (2026). Mechanistic insights into dual-active liver and blood-stage antiplasmodials. mBio, 17(1). https://doi.org/10.1128/mbio.02423-25

Vancouver

Rawat M, Boonyalai N, Smidt C, Luth MR, Chen D, Plater A, et al. Mechanistic insights into dual-active liver and blood-stage antiplasmodials. mBio. 2026;17(1). doi:10.1128/mbio.02423-25

BibTeX
@article{Rawat2026,
  author = {Rawat, Mukul and Boonyalai, Nonlawat and Smidt, Cindy and Luth, Madeline R and Chen, Daisy and Plater, Andrew and Post, John and Lin, De and McMillan, Joel and Eadsforth, Thomas and Moliner-Cubel, Sonia and Billker, Oliver and Rayner, Julian C and Gamo, Fransisco-Javier and Baragaña, Beatriz and Winzeler, Elizabeth A and Lee, Marcus C S},
  title = {Mechanistic insights into dual-active liver and blood-stage antiplasmodials},
  journal = {mBio},
  year = {2026},
  volume = {17},
  number = {1},
  doi = {10.1128/mbio.02423-25}
}
Kostenlos starten →